Join Growin Stock Community!

Immunovant, inc.IMVT.US Overview

US StockHealthcare
(No presentation for IMVT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

IMVT AI Insights

IMVT Overall Performance

IMVT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IMVT Recent Performance

0.86%

Immunovant, inc.

0.05%

Avg of Sector

-0.31%

S&P500

IMVT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

IMVT Key Information

IMVT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

IMVT Profile

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Price of IMVT

IMVT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IMVT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.28
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
5.72
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.28
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
5.72
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is IMVT's latest earnings report released?

    The most recent financial report for Immunovant, inc. (IMVT) covers the period of 2026Q3 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IMVT's short-term business performance and financial health. For the latest updates on IMVT's earnings releases, visit this page regularly.

  • How much cash does IMVT have?

    At the end of the period, Immunovant, inc. (IMVT) held Total Cash and Cash Equivalents of 994.53M, accounting for 0.95 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is IMVT's EPS continuing to grow?

    According to the past four quarterly reports, Immunovant, inc. (IMVT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.61. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of IMVT?

    Immunovant, inc. (IMVT)'s Free Cash Flow (FCF) for the period is -92.33M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 8.2% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of IMVT?

    The latest valuation data shows Immunovant, inc. (IMVT) has a Price-To-Earnings (PE) ratio of -11.86 and a Price/Earnings-To-Growth (PEG) ratio of 0.63. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.